Operator
Good afternoon, ladies and gentlemen, and welcome to the TELA Bio Fourth Quarter and Full Year 2025 Earnings Conference Call.
[Operator Instructions]
As a reminder, this conference call is being recorded. I would now like to turn the conference call over to Louisa Smith from Investor Relations.
Louisa Smith
Investor Relations Contact Officer
Thank you, Jonathan, and good afternoon, everyone. Earlier today, TELA Bio released financial results for the fourth quarter and full year ended December 31, 2025. A copy of the press release is available on the company’s website. Joining me on today’s call are Tony Koblish, Chief Executive Officer; Jeff Blizard, President; Roberto Cuca, Chief Operating Officer and Chief Financial Officer; and Jim Hagen, Senior Vice President of Strategic Operations and Marketing.
Before we begin, I’d like to remind you that during this conference call, the company may make projections and forward-looking statements regarding future events. We encourage you to review the company’s past and future filings with the SEC, including, without limitation, the company’s annual report on Form 10-K and quarterly reports on Forms 10-Q, which identify the specific risk factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, statements regarding product development, pipeline opportunities, sales and marketing strategies and the impact of various
